These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1529628)

  • 21. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial occlusions.
    Dawson KJ; Hamilton G
    Radiology; 1991 Jan; 178(1):283-4. PubMed ID: 1898537
    [No Abstract]   [Full Text] [Related]  

  • 24. Simultaneous measurement of all thrombosis parameters from native human blood: usefulness in monitoring efficacy and complications of thrombolytic therapy.
    Kovacs IB; Görög P
    Angiology; 1990 Oct; 41(10):829-35. PubMed ID: 2121073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolysis with recombinant tissue plasminogen activator in late saphenous vein graft thrombosis.
    Blanck Z; Cheirif J; Blick DR; Harris SL; Heibig J
    Am Heart J; 1990 Apr; 119(4):952-3. PubMed ID: 2138846
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of platelets and leukocytes in coagulation and fibrinolysis.
    Cucuianu M; Trif I
    Rev Roum Physiol (1990); 1992; 29(1-2):33-8. PubMed ID: 1472550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tissue-type plasminogen activator--biochemistry, physiology and clinical use].
    Gmiński J; Flak A
    Wiad Lek; 1989 Oct 1-Nov 1; 42(19-21):1055-9. PubMed ID: 2517807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated thrombolysis facilitated by direct puncture of occluded prosthetic femoral grafts.
    Page JE; Buckenham TM; Taylor RS
    Australas Radiol; 1992 Aug; 36(3):230-3. PubMed ID: 1445106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
    Stump DC; Topol EJ; Chen AB; Hopkins A; Collen D
    Thromb Haemost; 1988 Apr; 59(2):133-7. PubMed ID: 2455358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
    Aramoto H; Shigematsu H; Muto T
    Int J Cardiol; 1994 Dec; 47(1 Suppl):S55-63. PubMed ID: 7737753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolysis and the femorofemoral bypass graft: a new technique.
    Buckenham TM; George CD; Taylor RS; Dormandy JA
    Australas Radiol; 1992 May; 36(2):99-101. PubMed ID: 1520189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters.
    Seifried E; Tanswell P
    Thromb Haemost; 1987 Oct; 58(3):921-6. PubMed ID: 2448890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
    Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J
    Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
    Shebuski RJ; Storer BL; Fujita T
    Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis.
    Becker RC
    Cardiology; 1991; 79(3):188-210. PubMed ID: 1769035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study.
    Topol EJ; Bell WR; Weisfeldt ML
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):837-43. PubMed ID: 3933395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated thrombolysis using pulsed intra-thrombus recombinant human tissue type plasminogen activator (rt-PA).
    Buckenham TM; George CD; Chester JF; Taylor RS; Dormandy JA
    Eur J Vasc Surg; 1992 May; 6(3):237-40. PubMed ID: 1592125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.
    Marder VJ
    Am J Med; 1987 Aug; 83(2A):15-9. PubMed ID: 3115098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Local rt-PA infiltration of thrombotic vascular occlusions].
    Fischer M; Beer D; von Wrangell U
    Vasa Suppl; 1992; 35():188-9. PubMed ID: 1481042
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.